Assessment of Postnatal Corticosteroids for the Prevention of Bronchopulmonary Dysplasia in Preterm Neonates: A Systematic Review and Network Meta-analysis

Overview

Journal JAMA Pediatr

Publisher American Medical Association

Date 2021 Mar 15

PMID 33720274

Citations 40

Authors

Viraraghavan Vadakkencherry Ramaswamy

Tapas Bandyopadhyay

Debasish Nanda

Prathik Bandiya

Javed Ahmed

Anip Garg

Charles C Roehr

Sushma Nangia

Affiliations

Soon will be listed here.

Abstract

Importance: The safety of postnatal corticosteroids used for prevention of bronchopulmonary dysplasia (BPD) in preterm neonates is a controversial matter, and a risk-benefit balance needs to be struck.

Objective: To evaluate 14 corticosteroid regimens used to prevent BPD: moderately early-initiated, low cumulative dose of systemic dexamethasone (MoLdDX); moderately early-initiated, medium cumulative dose of systemic dexamethasone (MoMdDX); moderately early-initiated, high cumulative dose of systemic dexamethasone (MoHdDX); late-initiated, low cumulative dose of systemic dexamethasone (LaLdDX); late-initiated, medium cumulative dose of systemic dexamethasone (LaMdDX); late-initiated, high cumulative dose of systemic dexamethasone (LaHdDX); early-initiated systemic hydrocortisone (EHC); late-initiated systemic hydrocortisone (LHC); early-initiated inhaled budesonide (EIBUD); early-initiated inhaled beclomethasone (EIBEC); early-initiated inhaled fluticasone (EIFLUT); late-initiated inhaled budesonide (LIBUD); late-initiated inhaled beclomethasone (LIBEC); and intratracheal budesonide (ITBUD).

Data Sources: PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), Embase, World Health Organization's International Clinical Trials Registry Platform (ICTRP), and CINAHL were searched from inception through August 25, 2020.

Study Selection: In this systematic review and network meta-analysis, the randomized clinical trials selected included preterm neonates with a gestational age of 32 weeks or younger and for whom a corticosteroid regimen was initiated within 4 weeks of postnatal age. Peer-reviewed articles and abstracts in all languages were included.

Data Extraction And Synthesis: Two independent authors extracted data in duplicate. Network meta-analysis used a bayesian model.

Main Outcomes And Measures: Primary combined outcome was BPD, defined as oxygen requirement at 36 weeks' postmenstrual age (PMA), or mortality at 36 weeks' PMA. The secondary outcomes included 15 safety outcomes.

Results: A total of 62 studies involving 5559 neonates (mean [SD] gestational age, 26 [1] weeks) were included. Several regimens were associated with a decreased risk of BPD or mortality, including EHC (risk ratio [RR], 0.82; 95% credible interval [CrI], 0.68-0.97); EIFLUT (RR, 0.75; 95% CrI, 0.55-0.98); LaHdDX (RR, 0.70; 95% CrI, 0.54-0.87); MoHdDX (RR, 0.64; 95% CrI, 0.48-0.82); ITBUD (RR, 0.73; 95% CrI, 0.57-0.91); and MoMdDX (RR, 0.61; 95% CrI, 0.45-0.79). Surface under the cumulative ranking curve (SUCRA) value ranking showed that MoMdDX (SUCRA, 0.91), MoHdDX (SUCRA, 0.86), and LaHdDX (SUCRA, 0.76) were the 3 most beneficial interventions. ITBUD (RR, 4.36; 95% CrI, 1.04-12.90); LaHdDX (RR, 11.91; 95% CrI, 1.64-44.49); LaLdDX (RR, 6.33; 95% CrI, 1.62-18.56); MoHdDX (RR, 4.96; 95% CrI, 1.14-14.75); and MoMdDX (RR, 3.16; 95% CrI, 1.35-6.82) were associated with more successful extubation from invasive mechanical ventilation. EHC was associated with a higher risk of gastrointestinal perforation (RR, 2.77; 95% CrI, 1.09-9.32). MoMdDX showed a higher risk of hypertension (RR, 3.96; 95% CrI, 1.10-30.91). MoHdDX had a higher risk of hypertrophic cardiomyopathy (RR, 5.94; 95% CrI, 1.95-18.11).

Conclusions And Relevance: This study suggested that MoMdDX may be the most appropriate postnatal corticosteroid regimen for preventing BPD or mortality at a PMA of 36 weeks, albeit with a risk of hypertension. The quality of evidence was low.

Citing Articles

Validation of the NICHD Bronchopulmonary Dysplasia Outcome Estimator 2022 in a Quaternary Canadian NICU-A Single-Center Observational Study.

Kanagaraj U, Kulkarni T, Kwan E, Zhang Q, Bone J, Shivananda S J Clin Med. 2025; 14(3).

PMID: 39941365 PMC: 11818857. DOI: 10.3390/jcm14030696.

Neurodevelopmental Outcome at 20 Months Corrected Age in Extremely Preterm Infants After Exposure to Dexamethasone and Hydrocortisone in the NICU.

David J, Foschi C, Greene M, Click K, Hunsinger B, Patra K J Pediatr Pharmacol Ther. 2025; 30(1):84-92.

PMID: 39935572 PMC: 11809538. DOI: 10.5863/1551-6776-30.1.84.

Physiologic and structural characterization of desisobutyryl-ciclesonide, a selective glucocorticoid receptor modulator in newborn rats.

Jaumotte J, El Khoury N, Min C, Wang J, Madigan C, Jano A PNAS Nexus. 2025; 4(1):pgae573.

PMID: 39781096 PMC: 11707230. DOI: 10.1093/pnasnexus/pgae573.

A Comparison of the 2022 Versus 2011 National Institute of Child Health and Human Development Web-Based Risk Estimator for Bronchopulmonary Dysplasia.

Kinkor M, Schneider J, Sulthana F, Noel-MacDonnell J, Cuna A J Pediatr Clin Pract. 2024; 14:200129.

PMID: 39629201 PMC: 11613184. DOI: 10.1016/j.jpedcp.2024.200129.

Respiratory support and bronchopulmonary dysplasia in infants born at 22-26 weeks gestation in Sweden, 2004-2007 and 2014-2016.

Lofberg L, Abrahamsson T, Bjorklund L, Hellstrom Westas L, Farooqi A, Domellof M Eur Respir J. 2024; 65(1.

PMID: 39510555 PMC: 11736309. DOI: 10.1183/13993003.01203-2024.

References

Shinwell E, Portnov I, Meerpohl J, Karen T, Bassler D . Inhaled Corticosteroids for Bronchopulmonary Dysplasia: A Meta-analysis. Pediatrics. 2016; 138(6). DOI: 10.1542/peds.2016-2511. View

Onland W, De Jaegere A, Offringa M, van Kaam A . Systemic corticosteroid regimens for prevention of bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev. 2017; 1:CD010941. PMC: 6464844. DOI: 10.1002/14651858.CD010941.pub2. View

Halliday H, Patterson C, Halahakoon C . A multicenter, randomized open study of early corticosteroid treatment (OSECT) in preterm infants with respiratory illness: comparison of early and late treatment and of dexamethasone and inhaled budesonide. Pediatrics. 2001; 107(2):232-40. DOI: 10.1542/peds.107.2.232. View

Efird M, Heerens A, Gordon P, Bose C, Young D . A randomized-controlled trial of prophylactic hydrocortisone supplementation for the prevention of hypotension in extremely low birth weight infants. J Perinatol. 2004; 25(2):119-24. DOI: 10.1038/sj.jp.7211193. View

Romagnoli C, Zecca E, Vento G, De Carolis M, Papacci P, Tortorolo G . Early postnatal dexamethasone for the prevention of chronic lung disease in high-risk preterm infants. Intensive Care Med. 1999; 25(7):717-21. DOI: 10.1007/s001340050935. View

Bonsante F, Latorre G, Iacobelli S, Forziati V, Laforgia N, Esposito L . Early low-dose hydrocortisone in very preterm infants: a randomized, placebo-controlled trial. Neonatology. 2007; 91(4):217-21. DOI: 10.1159/000098168. View

Pan J, Chen M, Ni W, Fang T, Zhang H, Chen Y . [Clinical efficacy of pulmonary surfactant combined with budesonide for preventing bronchopulmonary dysplasia in very low birth weight infants]. Zhongguo Dang Dai Er Ke Za Zhi. 2017; 19(2):137-141. PMC: 7389465. View

Onland W, Offringa M, van Kaam A . Late (≥ 7 days) inhalation corticosteroids to reduce bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev. 2017; 8:CD002311. PMC: 6483527. DOI: 10.1002/14651858.CD002311.pub4. View

Baud O, Maury L, Lebail F, Ramful D, El Moussawi F, Nicaise C . Effect of early low-dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterm infants (PREMILOC): a double-blind, placebo-controlled, multicentre, randomised trial. Lancet. 2016; 387(10030):1827-36. DOI: 10.1016/S0140-6736(16)00202-6. View

10.

Shim S, Kim S, Lee J, Rucker G . Network meta-analysis: application and practice using R software. Epidemiol Health. 2019; 41:e2019013. PMC: 6635665. DOI: 10.4178/epih.e2019013. View

11.

Bloomfield F, Knight D, Harding J . Side effects of 2 different dexamethasone courses for preterm infants at risk of chronic lung disease: a randomized trial. J Pediatr. 1998; 133(3):395-400. DOI: 10.1016/s0022-3476(98)70277-x. View

12.

Armstrong D, Penrice J, Bloomfield F, Knight D, Dezoete J, Harding J . Follow up of a randomised trial of two different courses of dexamethasone for preterm babies at risk of chronic lung disease. Arch Dis Child Fetal Neonatal Ed. 2002; 86(2):F102-7. PMC: 1721382. DOI: 10.1136/fn.86.2.f102. View

13.

Papile L, BURSTEIN J, Burstein R, KOFFLER H . Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr. 1978; 92(4):529-34. DOI: 10.1016/s0022-3476(78)80282-0. View

14.

Dimitriou G, Greenough A, Giffin F, Kavadia V . Inhaled versus systemic steroids in chronic oxygen dependency of preterm infants. Eur J Pediatr. 1997; 156(1):51-5. DOI: 10.1007/s004310050552. View

15.

Zimmerman J, Gabbert D, Shivpuri C, Kayata S, Miller J, Ciesielski W . Meter-dosed, inhaled beclomethasone initiated at birth to prevent bronchopulmonary dysplasia. Pediatr Crit Care Med. 2003; 1(2):140-5. DOI: 10.1097/00130478-200010000-00009. View

16.

Brozanski B, Jones J, Gilmour C, Balsan M, Vazquez R, Israel B . Effect of pulse dexamethasone therapy on the incidence and severity of chronic lung disease in the very low birth weight infant. J Pediatr. 1995; 126(5 Pt 1):769-76. DOI: 10.1016/s0022-3476(95)70410-8. View

17.

Rozycki H, Byron P, Elliott G, Carroll T, Gutcher G . Randomized controlled trial of three different doses of aerosol beclomethasone versus systemic dexamethasone to promote extubation in ventilated premature infants. Pediatr Pulmonol. 2003; 35(5):375-83. DOI: 10.1002/ppul.10269. View

18.

Doyle L, Halliday H, Ehrenkranz R, Davis P, Sinclair J . An update on the impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk of bronchopulmonary dysplasia. J Pediatr. 2014; 165(6):1258-60. DOI: 10.1016/j.jpeds.2014.07.049. View

19.

Delara M, Chauhan B, Le M, Abou-Setta A, Zarychanski R, tJong G . Efficacy and safety of pulmonary application of corticosteroids in preterm infants with respiratory distress syndrome: a systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed. 2018; 104(2):F137-F144. DOI: 10.1136/archdischild-2017-314046. View

20.

LaForce W, Brudno D . Controlled trial of beclomethasone dipropionate by nebulization in oxygen- and ventilator-dependent infants. J Pediatr. 1993; 122(2):285-8. DOI: 10.1016/s0022-3476(06)80134-4. View